Medtronic Gains BioIntelliSense’s Continuous Vital Signs Monitor in Distribution Deal

Medtronic has begun a partnership with continuous health monitoring and clinical health intelligence firm BioIntelliSense wherein Medtronic will exclusively distribute the BioButton multi-parameter continuous, connected wearable monitoring device.
 
Terms of the deal weren’t disclosed.
 
BioButton performs up to 1,440 vital sign measurements daily including skin temperature, respiratory rate at rest, and rest heart rate. Advanced analytics programmed in the device help clinicians better spot early signs of deterioration or identify stable patients who can be discharged early. BioButton is rechargeable and has configurable acute and post-acute modes as patients transition through acuity settings.
 
“Our vision is to empower clinicians and patients with actionable insights to personalize care — anytime, anywhere,” Frank Chan, Ph.D., president of Medtronic’s Patient Monitoring business told the press. “Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will support continuous, connected care from in-hospital to home and expand our reach to help more patients in more places than ever before.”
 
Adding BioButton to Medtronic’s HealthCast connectivity gateway aims to help more general care patients both inside and outside the hospital with near real-time trend and alert data.
 
“In partnership with Medtronic, we are poised to accelerate continuous connected care models that offer a new level of clinical surveillance and workflow efficiencies for hospitals that are challenged in today’s environment of growing workforce shortages and cost of care management,” said James Mault, M.D., founder and CEO of BioIntelliSense. “This advanced remote physiologic monitoring simplifies care delivery to facilitate personalized patient care, clinical workflow automation and proactive clinical interventions.”